Search results
Results from the WOW.Com Content Network
The top 5 best selling pharmaceuticals 2015–2019. Sales in billion USD. [1] Rank Drug Main indication Trade name 2015 ... breast cancer: Herceptin 6981 7013 9
Breast cancer Pfizer: $465 $401 $320 $247 $143 $58 epirubicin: Ellence Breast cancer Pfizer: $312 $367 $344 $216 trastuzumab: Herceptin HER2-positive metastatic breast cancer Genentech: $1,382 $1,287 $1,234 $747.2 $483.2 $424.8 $385.2 $346.7 $276 gemcitabine: Gemzar
This list of top-selling drugs could look drastically different in a few years. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 more ways to ...
Refractory metastatic melanoma, childhood acute lymphoblastic leukaemia, chronic myeloid leukaemia in blast crises, neuroblastoma, non-small cell lung cancer and breast cancer. Myelosuppression, neurotoxicity and paralytic ileus. Vinflunine: IV: As above. Bladder cancer: As per vinblastine. Vinorelbine: IV: As above. Breast cancer and non-small ...
The trial, known as CAPItello-290, was testing whether the drug combination improved overall survival in patients with inoperable or metastatic triple-negative breast cancer versus the older and ...
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6. [4] It was designated as a breakthrough therapy for breast cancer by the US Food and Drug Administration (FDA) in ...
Palliative chemotherapy is used to control (but not cure) the cancer in settings in which the cancer has spread beyond the breast and localized lymph nodes. See metastatic breast cancer. Combined therapies These combine, for example, non-drug treatments with localized chemotherapy to limit toxicity and achieve better results. [3]
Letrozole, sold under the brand name Femara among others, is an aromatase inhibitor medication that is used in the treatment of breast cancer for post-menopausal women. [1]It was patented in 1986 and approved for medical use in 1996. [4]